Scythian Biosciences Corp (SCYB.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 09/30
| 03-2024 | 12-2023 | 09-2023 | 06-2023 | 03-2023 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 397 | 398 | 367 | 403 | 383 |
| Accounts receivable | -1,760 | 1,507 | 3,753 | -623 | -596 |
| Accounts payable and accrued liabilities | 724 | 36 | -5 | -393 | 2,023 |
| Other Working Capital | 1,241 | 1,596 | 5,185 | -3,994 | 1,369 |
| Other Operating Activity | -2,185 | -4,187 | -8,154 | -3,729 | -3,439 |
| Operating Cash Flow | $-1,584 | $-650 | $1,146 | $-8,336 | $-259 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 0 | 0 | -18 | -51 | -49 |
| Net Acquisitions | N/A | N/A | 165 | N/A | N/A |
| Other Investing Activity | 0 | 0 | -3 | -165 | 0 |
| Investing Cash Flow | $0 | $0 | $144 | $-216 | $-49 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | N/A | -36 | 92 | N/A | N/A |
| Common Stock Issued | 0 | 0 | -1,526 | 7,221 | 889 |
| Other Financing Activity | 1,931 | 336 | 433 | 547 | 1 |
| Financing Cash Flow | $1,931 | $300 | $-1,001 | $7,768 | $891 |
| Beginning Cash Position | 19 | 369 | 80 | 864 | 281 |
| End Cash Position | 366 | 19 | 369 | 80 | 864 |
| Net Cash Flow | $347 | $-351 | $289 | $-784 | $583 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,584 | -650 | 1,146 | -8,336 | -259 |
| Capital Expenditure | N/A | N/A | -18 | -51 | -49 |
| Free Cash Flow | -1,584 | -650 | 1,128 | -8,387 | -308 |